AstraZeneca Is Committed to Business in China, Says CEO

AstraZeneca is heavily investing in China, focusing on R&D, AI, and partnerships with local biotech firms. The company aims to align with Chinese government policies, expand its market presence, and support the import of innovative products. Despite challenges like the bulk buying program, AstraZeneca remains optimistic about growth, leveraging its strong pipeline and infrastructure. The evolving pharmaceutical landscape in China presents both opportunities and competition, with local companies rapidly innovating.

What challenges does AstraZeneca face in the competitive landscape of the Chinese pharmaceutical market?

What are AstraZeneca's long-term goals for its growth in the Chinese market?

How does AstraZeneca view the impact of global trade tensions on its operations in China?